VOC Diagnostics
VOC Diagnostics AB is a cancer diagnostics company specializing in early detection of ovarian cancer using a patented technology that analyzes volatile organic compounds (VOCs) from blood plasma samples. Founded in 2017 based on research at Gothenburg University, the company has developed a unique electronic nose method combined with machine learning to detect ovarian cancer with high sensitivity and specificity, outperforming existing methods. The company is advancing product development and clinical evidence collection to obtain regulatory approval in Europe, targeting market introduction by 2029. VOC Diagnostics also explores applications for other cancers such as breast, lung, and prostate cancer. The business model is primarily based on product development and commercialization, supported by grants and investments. The company collaborates with academic and clinical partners and has secured funding from Swedish and US innovation agencies. Key team members include CEO Lotta Tollstoy Tegler and CTO Jens Eriksson, with a board led by Chairman Nils Crona. VOC Diagnostics is positioned as a promising innovator in early cancer diagnostics with strong scientific backing and ongoing clinical studies.
VOC Diagnostics
VOC Diagnostics AB is a cancer diagnostics company specializing in early detection of ovarian cancer using a patented technology that analyzes volatile organic compounds (VOCs) from blood plasma samples. Founded in 2017 based on research at Gothenburg University, the company has developed a unique electronic nose method combined with machine learning to detect ovarian cancer with high sensitivity and specificity, outperforming existing methods. The company is advancing product development and clinical evidence collection to obtain regulatory approval in Europe, targeting market introduction by 2029. VOC Diagnostics also explores applications for other cancers such as breast, lung, and prostate cancer. The business model is primarily based on product development and commercialization, supported by grants and investments. The company collaborates with academic and clinical partners and has secured funding from Swedish and US innovation agencies. Key team members include CEO Lotta Tollstoy Tegler and CTO Jens Eriksson, with a board led by Chairman Nils Crona. VOC Diagnostics is positioned as a promising innovator in early cancer diagnostics with strong scientific backing and ongoing clinical studies.